Crossmark

Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus

Crossref DOI link: https://doi.org/10.1186/s40169-016-0125-2

Published Online: 2016-11-30

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Malecki, Marek

Putzer, Emily

Quach, Caroline

Dodivenaka, Chaitanya

Tombokan, Xenia
Funding

Funding for this research was provided by:

National Science Foundation (9420056, 9522771, 9902020, 0094016)

National Institutes of Health (P41 RR000570, P41 RR002301)
License Information

Accepted Manuscript valid from 2016-11-30

Version of Record valid from 2016-11-30

License valid from 2016-11-30